Nicholas A Lentini
Overview
Explore the profile of Nicholas A Lentini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
75
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang J, Riemann S, Lyu J, Feng S, Bi Y, Lentini N, et al.
bioRxiv
. 2024 Nov;
PMID: 39554161
Adenovirus infections of immunocompromised humans are a significant source of morbidity and mortality. At present, no drug has been approved by FDA for the treatment of adenovirus infections. A current...
2.
Okawa H, Kondo T, Hokugo A, Cherian P, Campagna J, Lentini N, et al.
Elife
. 2022 Aug;
11.
PMID: 36017995
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) presents as a morbid jawbone lesion in patients exposed to a nitrogen-containing bisphosphonate (N-BP). Although it is rare, BRONJ has caused apprehension among patients...
3.
Lentini N, Huang X, Schladetsch M, Hsiao C, Wiemer D, Wiemer A
Bioorg Med Chem Lett
. 2022 Apr;
66:128724.
PMID: 35405283
Bis-amidate derivatives have been viewed as attractive phosphonate prodrug forms because of their straightforward synthesis, lack of phosphorus stereochemistry, plasma stability and nontoxic amino acid metabolites. However, the efficiency of...
4.
Lentini N, Schroeder C, Harmon N, Huang X, Schladetsch M, Foust B, et al.
ACS Med Chem Lett
. 2021 Jan;
12(1):136-142.
PMID: 33488975
()-4-Hydroxy-3-methyl-but-2-enyl diphosphate (HMBPP) and its phosphonate analogs are potent phosphoantigens. HMBPP contains an ()-allylic alcohol which interacts with the molecular target BTN3A1 giving an antigenic signal to activate Vγ9Vδ2 T...
5.
Li J, Lentini N, Wiemer D, Wiemer A
Biochem Pharmacol
. 2019 Oct;
170:113668.
PMID: 31628909
Human Vγ9Vδ2 T cells respond to small phosphorus-containing compounds, often called phosphoantigens, which are now known to be intracellular ligands of the immune receptor butyrophilin 3A1 (BTN3A1). In order to...
6.
Lentini N, Hsiao C, Crull G, Wiemer A, Wiemer D
ACS Med Chem Lett
. 2019 Sep;
10(9):1284-1289.
PMID: 31531198
Aryloxy phosphonamidate derivatives of a butyrophilin 3A1 ligand are stimulants of Vγ9 Vδ2 T cells. However, when bonded to an aryl ester and an amine, the phosphorus is stereogenic, and...
7.
Lentini N, Foust B, Hsiao C, Wiemer A, Wiemer D
J Med Chem
. 2018 Sep;
61(19):8658-8669.
PMID: 30199251
Small organophosphorus compounds stimulate Vγ9 Vδ2 T cells if they serve as ligands of butyrophilin 3A1. Because the most potent natural ligand is ( E)-4-hydroxy-3-methyl-but-2-enyl diphosphate (HMBPP), which is the...
8.
Foust B, Poe M, Lentini N, Hsiao C, Wiemer A, Wiemer D
ACS Med Chem Lett
. 2017 Sep;
8(9):914-918.
PMID: 28947936
Studies of aryl phosphonate derivatives of a butyrophilin 3A1 ligand have resulted in identification of a potent stimulant of Vγ9 Vδ2 T cells. This compound, a mixed ester bearing one...